Oramed Pharmaceuticals (ORMP) Depreciation & Amortization (CF) (2010 - 2026)
Oramed Pharmaceuticals (ORMP) reported Depreciation & Amortization (CF) of $30000.0 for Q1 2026, little changed on a YoY basis from $30000.0 in Q1 2025, and little changed quarter-over-quarter from $30000.0 in Q4 2025.
Oramed Pharmaceuticals (ORMP) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Oramed Pharmaceuticals has reported Depreciation & Amortization (CF) for 17 years, with the latest figure at $30000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) changed 0.0% year-over-year to $30000.0; the trailing twelve-month figure through Mar 2026 stood at $121000.0 (down 27.54% YoY), and the FY2025 full-year result was $121000.0, down 37.31% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $30000.0, roughly flat from $30000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $56000.0 in Q1 2024, with the low at $11000.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $35176.5 across 5 years, with a median of $31000.0 in 2024.
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) surged 260.0% — and 2025, when it sank 46.43%.
- Oramed Pharmaceuticals' Depreciation & Amortization (CF) stood at $17000.0 in 2022, then surged by 211.76% to $53000.0 in 2023, then slumped by 41.51% to $31000.0 in 2024, then dropped by 3.23% to $30000.0 in 2025, then changed by 0.0% to $30000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $30000.0 (Q1 2026), $30000.0 (Q4 2025), and $31000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 429,663.65 |
| 10 | Oramed Pharmaceuticals | 151.47 Mn | 133.31 Mn | - | 30,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30,000.00 |
| Mar 31, 2026 | 30,000.00 |
| Dec 31, 2025 | 30,000.00 |
| Dec 31, 2025 | 30,000.00 |
| Sep 30, 2025 | 31,000.00 |
| Sep 30, 2025 | 31,000.00 |
| Jun 30, 2025 | 30,000.00 |
| Jun 30, 2025 | 30,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Dec 31, 2024 | 31,000.00 |
| Dec 31, 2024 | 31,000.00 |
| Sep 30, 2024 | 52,000.00 |
| Sep 30, 2024 | 52,000.00 |
| Jun 30, 2024 | 54,000.00 |
| Jun 30, 2024 | 54,000.00 |
| Mar 31, 2024 | 56,000.00 |
| Mar 31, 2024 | 56,000.00 |
| Dec 31, 2023 | 53,000.00 |
| Dec 31, 2023 | 53,000.00 |